Gentamicin, a widely used antibiotic, is used in U.S. hospitals to treat a variety of bacterial infections, including infections in newborns and in other susceptible patients, such as those with cystic fibrosis.
It’s a popular drug in developing countries because it is highly effective and inexpensive.
Yet researchers estimate that up to 20% of patients who are treated with it experience some degree of irreversible hearing loss.
In a new study, researchers found a new method of purifying gentamicin reduces the risk that it will cause deafness.
They found a relatively inexpensive way to reformulate the drug, which belongs to a class of antibiotics called aminoglycosides, to be safer.
The research was conducted by a team at Stanford Medicine.
Currently, the FDA’s instructions for how to make aminoglycosides are making people go deaf.
Aminoglycosides have been in use since the 1950s. The drugs don’t need to be refrigerated, which keeps the costs of storing them low.
Despite new antibiotics, their use remains commonplace as they are cheap and potent.
These drugs are used because they save a lot of lives. Scientists have stopped paying attention to their toxic side effects because living with hearing loss is better than dying.
The gentamicin used in hospitals today is a mixture of five different subtypes of the antibiotic grown together in the same mixture.
The mixture also includes as much as 10% impurities.
Using several methods, the researchers tried to figure out how to chemically separate each of the subtypes so they could be tested separately.
They found the least toxic subtype as C2b, and the most toxic as sisomicin.
Both C2b and sisomicin showed the same highly effective antimicrobial properties comparable to the mixture as a whole.
The researchers also found that by removing impurities from the mixture, toxicity to the ear tissue was reduced.
The team says when a drug causes hearing loss, it is devastating, and it’s especially disturbing when it happens to a young child, as they rely on hearing to acquire speech.
Their simple method of reformulating the drug should be put to use as soon as possible.
The researchers will be writing to the Food and Drug Administration to recommend changes to the organization’s requirements for how drug companies make gentamicin.
The researchers are also working on plans to create a new aminoglycoside that could further reduce the risk of hearing loss.
One author of the study is Alan Cheng, MD, a professor of otolaryngology.
The study is published in the Proceedings of the National Academy of Sciences.
Copyright © 2020 Knowridge Science Report. All rights reserved.